opioids

First Opinion By Mason Marks

FDA’s kratom ban would harm the public and damage the agency’s credibility

Pharmalot By Ed Silverman

David Sackler acknowledges ‘moral responsibility’ to address opioid crisis, but refuses to pay settlement without immunity

First Opinion By Sika Yeboah-Sampong and Gail D'Onofrio

Medically, legally, and morally, emergency departments cannot ignore addiction care

First Opinion By William Cooke

Harm-reduction programs acknowledge the difference between ‘do no harm’ and ‘protect from harm’

Health By Kevin Lin

Overdose data, often scattered and siloed, pose challenges for researchers racing to predict risk

Health By Andrew Joseph

States could get billions from opioid lawsuits. They have to decide how to spend it

First Opinion Podcast By Patrick Skerrett

Listen: A journalist on what the Vietnam War taught us about addiction

Pharmalot By Ed Silverman

Purdue says most creditors voted in favor of contentious bankruptcy plan

Health By Claudia López Lloreda

In the same health system, Black patients are prescribed fewer opioids than white patients

Pharmalot By Ed Silverman

States reach $26 billion deal with three wholesalers and J&J to end opioid lawsuits

Pharmalot By Ed Silverman

Three pharma wholesalers reach a $1.1 billion deal with New York over the opioid crisis

Pharmalot By Ed Silverman

As a key hearing nears, Justice Department calls Purdue’s bankruptcy plan unconstitutional

First Opinion By Lauren Aguirre

Lessons learned — and lost — from a Vietnam-era study of addiction

Pharmalot By Ed Silverman

Amid Purdue bankruptcy talks, Connecticut attorney general accuses some Sacklers of intimidation

Health By Mike Stobbe — Associated Press

U.S. overdose deaths hit record 93,000 in 2020 during pandemic

Politics By Lev Facher

Biden to nominate West Virginia’s Rahul Gupta as drug czar 

Pharmalot By Ed Silverman

Purdue reaches deal with 15 states in a significant step toward bankruptcy plan approval

Pharmalot By Ed Silverman

Purdue wants to shower employees with nearly $35 million in different kinds of bonuses

Pharmalot By Ed Silverman

Johnson & Johnson agrees to pay $230 million to settle opioid case in New York

First Opinion By William Cooke and Gregg Gonsalves

Closing an Indiana county’s syringe services program would be a public health disaster

Pharmalot By Ed Silverman

Massachusetts sues Publicis for designing ‘marketing schemes’ to boost OxyContin sales

First Opinion By Regina LaBelle, Tom Coderre and Rochelle Walensky

Unlocking federal funding for fentanyl test strips will save lives

First Opinion By David Eddie and John Kelly

People recover from addiction. They also go on to do good things

First Opinion By Thomas McLellan and Jacob Crothers

Needed: an Operation Warp Speed for the opioid epidemic

Politics By Lev Facher

Biden administration will allow nearly all providers to prescribe buprenorphine